Scenesse Approval Buoys Clinuvel As It Fights Retrophin
This article was originally published in PharmAsia News
Executive Summary
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.